$420M fund comes to LYFE, with plans for a trans-Pa­cif­ic in­vest­ment strat­e­gy in­tro­duc­ing US biotechs to Chi­na

Less than two years af­ter its launch, Shang­hai-based LYFE Cap­i­tal has come up with an up­sized biotech ven­ture fund. And this time it’s spread­ing its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.